An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

NCT02472145 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

326

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Decitabine 20 mg/m^2
DRUG: Talacotuzumab 9 mg/kg

Sponsor

Janssen Research & Development, LLC